SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (441)11/12/1998 12:06:00 PM
From: OldAIMGuy  Respond to of 1154
 
Hi Mike, Thanks for the link. Continuing good news will eventually overcome the market's ignorance of GENE.

Best regards, Tom



To: Mike McFarland who wrote (441)11/13/1998 7:46:00 AM
From: a. paisley  Read Replies (1) | Respond to of 1154
 
a great story didn t buy enough at 2.25



To: Mike McFarland who wrote (441)12/3/1998 2:15:00 AM
From: Larry Liebman  Read Replies (1) | Respond to of 1154
 
GENE
Valuation $62 million
Cash $34 million
Tech value $28 million

Considering they spend $30 million/yr on R&D, have some significant big pharma partners, positive press releases, etc., it seems that at $3 1/2/sh, GENE offers a positive risk/reward opportunity. I'm adding shares at <$3.50. Opinions?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News